ChemFeeds Site Navigation:
Journal Selection:
Search:

1) Acknowledgment to Reviewers (Molecular Cancer Therapeutics) Thursday December 4th 2014


2) Targeted Drug Discovery with TCGA, CMap, and CCLE (Molecular Cancer Therapeutics) Thursday December 4th 2014


3) Mouse Model of Human Lymphoma Therapy Heterogeneity (Molecular Cancer Therapeutics) Thursday December 4th 2014


4) BRAFV600E Blood Test (Molecular Cancer Therapeutics) Thursday December 4th 2014


5) Combinatorial Targeting of Notch1 and Ras/MAPK in Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


6) miR-185 Is a Potential Target for TNBC Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


7) Outcomes of Phase I Trials in Triple-Negative Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


8) Role of miR24 in Nasopharyngeal Carcinoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


9) miR141-CXCL1-CXCR2 Recruits Tregs in MPE (Molecular Cancer Therapeutics) Thursday December 4th 2014


10) miR200c Induces MDR and Metastasis (Molecular Cancer Therapeutics) Thursday December 4th 2014


11) Akt-Activated Endothelium and Bevacizumab in Ovarian Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


12) Doxycycline and Hepatocellular Carcinoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


13) MEK1 Gene Mutation and Gastric Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


14) PTENP1 as ceRNA in ccRCC (Molecular Cancer Therapeutics) Thursday December 4th 2014


15) ADAM9 in Gastric Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


16) Cellular Role of A687V EZH2 in ALL (Molecular Cancer Therapeutics) Thursday December 4th 2014


17) RRAD Induces Temozolomide Resistance of Glioblastoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


18) JAK1/STAT3 as a Therapeutic Target in Ovarian Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


19) Rapamycin Augments Antiglioma Immunotherapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


20) CBS9106-Induced CRM1 Degradation Requires CRL Activity (Molecular Cancer Therapeutics) Thursday December 4th 2014


21) GEP Antibody and Chemosensitization (Molecular Cancer Therapeutics) Thursday December 4th 2014


22) ADC Targeting LIV-1 for Breast Cancer (Molecular Cancer Therapeutics) Thursday December 4th 2014


23) Tivantinib Overcomes Drug Resistance by ABC Transporter (Molecular Cancer Therapeutics) Thursday December 4th 2014


24) Selective Radioprotection of Normal Tissues (Molecular Cancer Therapeutics) Thursday December 4th 2014


25) Cannabinoid Activity in an Orthotopic Murine Glioma Model (Molecular Cancer Therapeutics) Thursday December 4th 2014


26) C. vasculum Compounds Possess Antitumor Potential (Molecular Cancer Therapeutics) Thursday December 4th 2014


27) Ashwagandha Inhibits Metastasis and Angiogenesis (Molecular Cancer Therapeutics) Thursday December 4th 2014


28) Novel Pan-ERBB Inhibitor for Treating Glioblastoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


29) Alectinib Is a Potent Inhibitor of RET (Molecular Cancer Therapeutics) Thursday December 4th 2014


30) Cathepsin K Inhibitor for Metastatic Bone Disease (Molecular Cancer Therapeutics) Thursday December 4th 2014


31) Carfilzomib and Ricolinostat in NHL Cells (Molecular Cancer Therapeutics) Thursday December 4th 2014


32) In Vivo KRAS Silencing with siRNA (Molecular Cancer Therapeutics) Thursday December 4th 2014


33) Antitumor by Phage Protein-Targeting Micellar Paclitaxel (Molecular Cancer Therapeutics) Thursday December 4th 2014


34) PET Imaging of {beta}G Activity for Prodrug Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


35) Combination Therapy for KIT-Mutant Mast Cells (Molecular Cancer Therapeutics) Thursday December 4th 2014


36) NT157 Suppresses IRS1/2 and Augments Prostate Cancer Therapeutic Response (Molecular Cancer Therapeutics) Thursday December 4th 2014


37) Targeting PCNA for Cancer Therapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


38) Inhibition of MCT1 Potentiates Radiotherapy (Molecular Cancer Therapeutics) Thursday December 4th 2014


39) AT13387 Delays and Overcomes Resistance in Melanoma Models (Molecular Cancer Therapeutics) Thursday December 4th 2014


40) Vorinostat Decreases CD30 and Brentuximab Vedotin Efficacy (Molecular Cancer Therapeutics) Thursday December 4th 2014


41) BRAF Mutations and Immunity in Melanoma (Molecular Cancer Therapeutics) Thursday December 4th 2014


42) Correction: The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells (Molecular Cancer Therapeutics) Tuesday November 4th 2014


43) PDT with a Glucose-Conjugated Chlorin for GIST--Response (Molecular Cancer Therapeutics) Tuesday November 4th 2014


44) PDT with a Glucose-Conjugated Chlorin for GIST--Letter (Molecular Cancer Therapeutics) Tuesday November 4th 2014


45) Stromal Targets of Multikinase Inhibitors (Molecular Cancer Therapeutics) Tuesday November 4th 2014


46) PI3K Pathway Inhibition and Resistance Mechanisms in HNSCC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


47) Camptothecin Tissue Penetration and Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


48) The SNAI2:miR145 Axis and Chemotherapeutic Response (Molecular Cancer Therapeutics) Tuesday November 4th 2014


49) The Effect of Irradiation on Multidrug Resistance (Molecular Cancer Therapeutics) Tuesday November 4th 2014


50) Fn14-Targeted Therapeutics (Molecular Cancer Therapeutics) Tuesday November 4th 2014


51) Triple Fusion Protein Targeting Angiogenesis (Molecular Cancer Therapeutics) Tuesday November 4th 2014


52) MEDI-573, Alone or with mTOR Inhibitors, Targets Sarcoma IGF (Molecular Cancer Therapeutics) Tuesday November 4th 2014


53) RG7787 in Gastric and Triple-Negative Breast Cancers (Molecular Cancer Therapeutics) Tuesday November 4th 2014


54) An Antibody-Cytokine-Drug Con{#x0237}ugate with Antitumor Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


55) Preclinically Efficacious Antimesothelin-MMAE Con{#x0237}ugate (Molecular Cancer Therapeutics) Tuesday November 4th 2014


56) Preclinical Profile of SYD983/SYD985 (Molecular Cancer Therapeutics) Tuesday November 4th 2014


57) Anti-MET ImmunoPET (Molecular Cancer Therapeutics) Tuesday November 4th 2014


58) Optical Imaging of Prostate Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


59) Inhibition of PSCs by Bisphosphonates in PDAC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


60) Targeting MLL5{beta} for Cervical Cancer Therapy (Molecular Cancer Therapeutics) Tuesday November 4th 2014


61) Monensin Enhances Erlotinib Activity (Molecular Cancer Therapeutics) Tuesday November 4th 2014


62) Efficacy of CH5183284 against Tumors with FGFR Aberrations (Molecular Cancer Therapeutics) Tuesday November 4th 2014


63) Small Molecule Pol I Inhibitors (Molecular Cancer Therapeutics) Tuesday November 4th 2014


64) Pazopanib for FGFR2 Amplification in Gastric Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


65) SEMs for the Treatment of Tamoxifen-Resistant Breast Cancer (Molecular Cancer Therapeutics) Tuesday November 4th 2014


66) Targeting Hypoxia and HR Repair Defects in TNBC (Molecular Cancer Therapeutics) Tuesday November 4th 2014


67) Targeting mTOR Kinase/IGF1R Feedback in Multiple Myeloma (Molecular Cancer Therapeutics) Tuesday November 4th 2014


68) Feedback Loops and Drug Resistance (Molecular Cancer Therapeutics) Tuesday November 4th 2014


69) STK11-Driven Regulation of PDE4D (Molecular Cancer Therapeutics) Thursday October 2nd 2014


70) Zebrafish Antilymphatic Drug Screen (Molecular Cancer Therapeutics) Thursday October 2nd 2014


71) Integrin Deregulation by the Anticancer Gallium Compound KP46 (Molecular Cancer Therapeutics) Thursday October 2nd 2014


72) Regulation of NF-{kappa}B Activation by Piperlongumine (Molecular Cancer Therapeutics) Thursday October 2nd 2014


73) BRCA2 and Gemcitabine (Molecular Cancer Therapeutics) Thursday October 2nd 2014


74) P-Glycoprotein Mediated Resistance to Temozolomide in GBM (Molecular Cancer Therapeutics) Thursday October 2nd 2014


75) OSU-03012 and ER Stress (Molecular Cancer Therapeutics) Thursday October 2nd 2014


76) PTTG1 and Response to Paclitaxel Treatment (Molecular Cancer Therapeutics) Thursday October 2nd 2014


77) Lipid Catabolism Blockade Effects in Prostate Cancer (Molecular Cancer Therapeutics) Thursday October 2nd 2014


78) miR34-Based Cancer Therapy Candidate (Molecular Cancer Therapeutics) Thursday October 2nd 2014


79) IFN{alpha} Enhances T-Cell Killing of Solid Cancers (Molecular Cancer Therapeutics) Thursday October 2nd 2014


80) Targeting Melanoma with Nanolipolee-007 (Molecular Cancer Therapeutics) Thursday October 2nd 2014


81) BET Antagonist and FLT3-TKI against AML Cells (Molecular Cancer Therapeutics) Thursday October 2nd 2014


82) ICG-001 Inhibits Pancreatic Cancer Growth (Molecular Cancer Therapeutics) Thursday October 2nd 2014


83) Simvastatin and Metformin Combination Chemotherapy (Molecular Cancer Therapeutics) Thursday October 2nd 2014


84) Fludarabine Phosphate Repurposed for GIST (Molecular Cancer Therapeutics) Thursday October 2nd 2014


85) Targeting Endoglin in Pancreatic Cancer (Molecular Cancer Therapeutics) Thursday October 2nd 2014


86) Target Vemurafenib Resistance by the CDK4/6 Inhibitor LY2835219 (Molecular Cancer Therapeutics) Thursday October 2nd 2014


87) Correction: The Phosphoinositide 3-Kinase {alpha} Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


88) Correction: Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


89) Correction: Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-{kappa}B Activation, and Is Active in Patient-Derived Xenograft Models (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


90) Predictive Value of EGFL7 in mCRC (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


91) Pharmacogenetic Predictors in Early-Stage Colon Cancer (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


92) Biomarker for CBP501 (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


93) Combination of Quinacrine and Erlotinib in NSCLC (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


94) Novel Human Fusion Protein Kills EpCAM-Positive Cancer Cells (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


95) CDK4/6 Inhibitor Reduces Human Liposarcoma Growth (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


96) Dose Schedule Optimization with Combined MLN8237 and Taxanes (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


97) Cyclopamine Glucuronide Prodrug toward Glioma Stem Cells (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


98) NIR Fluorescent Choline Kinase Inhibitor (Molecular Cancer Therapeutics) Wednesday September 3rd 2014


View: prev | next

#RealTimeChem:

Announcements:

Chem News Feed:

Sunrise still later after Winter Solstice

A Molecular Shuttle with Fluorescence Output

DuPont Names Spin-off ‘Chemours’

12/19/14 PHD comic: 'Holiday Plan'

Flexible White Organic LEDs Achieve Record Efficiencies

Here’s something we’re sure many of our readers will find...

Smartphone Microscope Sizes Up Single DNA Molecules

A Chemjobber holiday tradition

A neat ozone+UV paper pointed out by See Arr Oh

Officials scramble to respond to Bangladesh oil spill

Merck, Cubist, and Hospira: The Inside

Another Alzheimer's Antibody Goes Down

Podcast: The top science news stories of 2014

Less tasty shrimp, thanks to climate change

Science in the spotlight as New York state bans fracking


Mitch Andre Garcia's Chem Feeds 2008-present

Some images have been reproduced by permission of The Royal Society of Chemistry. (RSC' RSS Policy)
Other images have been reproduced with permission of the American Chemical Society. (ACS' RSS Policy)
Few images have been reproduced with pending permission of Wiley-VCH. ()